Corvus Pharmaceuticals, Inc. (CRVS) stock
CRVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.19+0.02 (+0.20%)
Close on Nov 18, 2026Market cap $857.19MP/E –Yield –
Corvus Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
No revenue figures for Corvus Pharmaceuticals
Corvus Pharmaceuticals has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?